A detailed history of Steigerwald, Gordon & Koch Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Steigerwald, Gordon & Koch Inc. holds 3,094 shares of ABBV stock, worth $517,471. This represents 0.07% of its overall portfolio holdings.

Number of Shares
3,094
Previous 2,931 5.56%
Holding current value
$517,471
Previous $454,000 24.01%
% of portfolio
0.07%
Previous 0.06%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 16, 2024

BUY
$159.82 - $182.1 $26,050 - $29,682
163 Added 5.56%
3,094 $563,000
Q4 2023

Jan 16, 2024

SELL
$137.6 - $154.97 $16,924 - $19,061
-123 Reduced 4.03%
2,931 $454,000
Q3 2023

Oct 11, 2023

BUY
$133.59 - $154.65 $101,127 - $117,070
757 Added 32.96%
3,054 $455,000
Q2 2023

Jul 17, 2023

BUY
$132.51 - $164.9 $8,348 - $10,388
63 Added 2.82%
2,297 $309,000
Q1 2023

Apr 19, 2023

SELL
$144.61 - $166.54 $578 - $666
-4 Reduced 0.18%
2,234 $356,000
Q4 2022

Jan 17, 2023

BUY
$138.31 - $165.87 $23,097 - $27,700
167 Added 8.06%
2,238 $0
Q3 2022

Oct 12, 2022

BUY
$134.21 - $153.93 $4,965 - $5,695
37 Added 1.82%
2,071 $278,000
Q2 2022

Jul 14, 2022

SELL
$137.62 - $174.96 $9,082 - $11,547
-66 Reduced 3.14%
2,034 $312,000
Q1 2022

Apr 25, 2022

SELL
$131.98 - $163.75 $1,847 - $2,292
-14 Reduced 0.66%
2,100 $340,000
Q4 2021

Jan 26, 2022

BUY
$107.43 - $135.93 $859 - $1,087
8 Added 0.38%
2,114 $286,000
Q3 2021

Oct 18, 2021

BUY
$106.4 - $120.78 $4,468 - $5,072
42 Added 2.03%
2,106 $227,000
Q1 2021

Apr 27, 2021

SELL
$102.3 - $112.62 $5,012 - $5,518
-49 Reduced 2.32%
2,064 $223,000
Q4 2020

Jan 22, 2021

SELL
$80.49 - $108.67 $13,924 - $18,799
-173 Reduced 7.57%
2,113 $226,000
Q3 2020

Oct 14, 2020

BUY
$85.91 - $100.83 $12,027 - $14,116
140 Added 6.52%
2,286 $200,000
Q2 2020

Jul 14, 2020

BUY
$73.37 - $98.18 $157,452 - $210,694
2,146 New
2,146 $211,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $296B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Steigerwald, Gordon & Koch Inc. Portfolio

Follow Steigerwald, Gordon & Koch Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Steigerwald, Gordon & Koch Inc., based on Form 13F filings with the SEC.

News

Stay updated on Steigerwald, Gordon & Koch Inc. with notifications on news.